There certainly is an element of risk included. Yet, personally I deem it pretty small as the main idea of sozinibercept - that‘s blocking the VEGF-C pathway - holds true for all anti-VEGF-A agents - be it Lucentis, Eylea, Avastin, Beovu or Fabysmo - as they all lead to an unintended upregulation of VEGF-C as the main escape pathway of progressing angionesis.
There certainly is an element of risk included. Yet, personally...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.020(5.19%) |
Mkt cap ! $492.4M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 40.5¢ | 38.5¢ | $406.5K | 1.020M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 62482 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 11162 | 5 |
View Market Depth
| Last trade - 14.57pm 24/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |